Zepbound for Sleep Apnea: The First Drug Approved for OSA

The approval

What the FDA Approved

On December 20, 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity (BMI ≥ 30 kg/m²) — the first pharmacotherapy ever approved for OSA.

The indication is specific: it treats OSA as part of obesity management. It is not approved for OSA in patients without obesity.

Dosing follows the standard tirzepatide titration schedule used for obesity, up to 10 mg or 15 mg weekly as tolerated.

The data

What SURMOUNT-OSA Showed

Two Phase 3 trials, published in 2024, randomized 469 adults with obesity and moderate-to-severe OSA to tirzepatide or placebo. Trial 1 included patients not using CPAP; Trial 2 included patients on stable CPAP.

At 52 weeks, tirzepatide reduced apnea-hypopnea index (AHI) by approximately 25–29 events/hour vs. ~5–6 events/hour with placebo — roughly a two-thirds reduction.

Approximately 43–52% of tirzepatide-treated patients met criteria for disease resolution (AHI <5/hour, or AHI 5–14 without daytime sleepiness) at one year.

Mean weight loss in the trials was ~18–20% of body weight, consistent with SURMOUNT-1 findings.

Sleep symptoms (Epworth Sleepiness Scale, sleep-related impact on daily function), blood pressure, hsCRP, and lipid profile all improved meaningfully.

Who qualifies

Who Should Consider This

Strong candidates: adults with BMI ≥ 30 and moderate-to-severe OSA (AHI ≥ 15) who would benefit from obesity treatment regardless, and who either cannot tolerate CPAP or are seeking to reduce CPAP dependence over time.

Reasonable candidates: adults with BMI ≥ 30 and OSA already on CPAP who want to address the underlying obesity contributor and potentially reduce or eliminate CPAP requirement over time.

Not candidates: adults at normal weight with OSA — Zepbound is not indicated. Adults with the standard tirzepatide contraindications (personal/family history of medullary thyroid cancer, MEN 2, active pancreatitis).

Practical

What This Means for CPAP Decisions

CPAP remains the standard immediate intervention for moderate-to-severe OSA. Zepbound does not replace it acutely — weight loss takes months, and untreated severe OSA carries cardiovascular, cognitive, and motor-vehicle accident risk that warrants immediate management.

The realistic positioning: continue CPAP through the weight-loss period, reassess OSA with repeat sleep study at 6–12 months once weight has stabilized, and adjust CPAP requirement based on objective AHI rather than weight alone.

Many SURMOUNT-OSA patients achieved disease resolution but the trials were not designed to demonstrate cardiovascular outcome equivalence with CPAP. Decisions about discontinuing CPAP after weight loss should be based on repeat polysomnography and pulmonology guidance.

Insurance

Insurance Coverage Implications

The OSA indication opens a separate coverage pathway from the obesity indication. Some payers that decline weight-loss medication coverage may cover Zepbound under the OSA indication if criteria (BMI ≥ 30, documented OSA) are met.

Prior authorization is typically required and may demand documented prior CPAP trial or intolerance. Coverage is evolving rapidly in 2025–2026.